drugset / Trial / NCT01747642
Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Oncoxin in combination with Surafenib is safe and results in improved survival in patients with hepatocellular carcinoma (HCC)
Timeline
- Start
- 2012-12
- Primary completion
- 2013-12
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sorafenib | Small molecule | 200 mg | Oral |
Indications
No indication recorded.